Ad
Search
Generic filters
Filter by content type
Taxonomy terms

VLON – Vallon Pharmaceuticals Inc

🔒

Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month

Ad
N/A

1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Total Analysts: 1

Company Profile

Vallon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is primarily focused on the development and commercialization of biopharmaceutical products. It is focused on developing prescription drugs for central nervous system (CNS) disorders. Its clinical-stage product is Abuse-Deterrent Amphetamine Immediate-Release (ADAIR), an abuse-deterrent oral formulation of immediate-release (short-acting) dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The Company is also focused on developing other abuse-deterrent products, including the development of an ADMIR, an abuse deterrent formulation of methylphenidate (Ritalin), for the treatment of ADHD. ADAIR is being designed as a formulation to deter attempts to crush and snort and provides barriers to injection.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan

Ad

Responses